We are conducting clinical trials for our personalized cancer vaccines under the Expanded Access scheme. Patient's tumor from biopsies and matched normal blood sample are taken for genomic profiling, neoantigen identifications, and personalized vaccine design. The cancer vaccine are designed specifically based on the patient's tumor neoantigens and has been selected for maximal immunological response against the tumor.  Neoantigen vaccine for each patient is manufactured under good manufacturing practices (GMP) and administered by a qualified medical professional at the Seqker's network hospitals. Seqker will only charge for the costs that have been justified by an ethical committee and limited to those necessary to recover costs of genomic profiling, vaccine design, and vaccine manufacture.